ArticleJournal of global infectious diseases
Prevalence and Risk Factors of Liver Fibrosis in People Living with HIV/Acquired Immunodeficiency Syndrome.
Article in Journal of global infectious diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: With Antiretroviral therapy (ART), life expectancy in people living with HIV/acquired immunodeficiency syndrome (PLHA) has improved, shifting focus to complications like liver fibrosis. Contributing factors include HIV, ART-related metabolic changes, chronic inflammation, and co-infections (hepatitis B virus [HBV]/hepatitis C virus). However, HIV's independent role in fibrosis without traditional risk factors remains unclear. This study estimated liver fibrosis prevalence among PLHA in North India and identified associated risk factors. Methods: A cross-sectional study was conducted over 18 months at a tertiary ART center, including 354 PLHA. Liver fibrosis was assessed using FibroScan Results: The mean liver stiffness was 6.27 ± 1.87 kPa. Fibrosis stages included: F0-F1 (81.4%), F2 (13.6%), F3 (4.5%), and F4 (0.6%). Among HIV monoinfected patients without conventional risk factors, 12% had significant fibrosis, compared to 34% with risk factors ( Conclusion: Liver fibrosis was present in 18.7% of PLHA. Metabolic syndrome, diabetes, and HBV were key contributors. Routine fibrosis screening should be part of HIV care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.